Biotechnology company innovates treatment for pets with lumps, bumps and cancer
COLUMBIA, Md., (June 11, 2024) — 
TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Pre-Seed Builder Fund investment in Kubanda Cryotherapy. The Pre-Seed Builder Fund is housed under TEDCO’s Social Impact Funds, which were created to engage and invest in economically underserved founders and communities.
“Most pet tumors go untreated, and existing treatment options are inaccessible due to high costs and slow healing times,” said Bailey Surtees, CEO of Kubanda Cryotherapy. “We saw this gap in care and built an alternative, non-surgical solution, which offers less down time and better healing outcomes for pets. With TEDCO’s support, we can continue our mission of breaking down barriers to high-quality care.”
Kubanda Cryotherapy, located in Baltimore, Md., has developed a minimally invasive treatment for lumps, bumps and tumors in pets. Using cryoablation technology, their innovation works to kill cells through the formation of intracellular ice crystals. This procedure could offer faster healing time than surgery, chemo, or radiation procedures, and costs a fraction of the price for pet parents, broadening access to care.
“Kubanda Cryotherapy’s innovation offers a solution that can be used by many veterinarians,” said Jean-Luc Park, senior director of TEDCO’s Social Impact Funds. “Such a promising technology is starting in the veterinary clinic and could explore other healthcare sectors.”
Kubanda Cryotherapy has utilized several of TEDCO’s resources, including the Maryland Innovation Initiative (MII), where they received a Company Formation award, and the SBIR/STTR Proposal Lab.
Builder Fund companies receive access to resources such as hands-on executive support, peer-to-peer mentoring and collaboration, and networking opportunities. For information about TEDCO’s Builder Fund, visit https://www.tedcomd.com/funding/builder-fund.